ERBB2 and breast cancer: For instance, ARV-471 therapy was well-tolerated and showed antitumor activity in patients with ER+/HER2- locally advanced or metastatic BC in a phase I clinical trial 313; current phase III trials are evaluating its utility in locally advanced and metastatic BC 314.